INVENTIVA

Inventiva secures up to €348m ($380m) to complete Phase III trial for lanifibranor in MASH, with $103.4m immediate and $30m in milestone payments. Lanifibranor, an orally administered PPAR agonist, aims to treat MASH and F2/F3 liver fibrosis, with trial expected to conclude in H2 2026. The financing reflects investor confidence in lanifibranor's potential as a breakthrough therapy for MASH.

Inventiva secures €94.1 million of up to €348 million in equity financing to fund Phase 3 NATiV3 trial for lanifibranor in MASH, with over 1,100 patients enrolled; appoints Mark Pruzanski, MD as Chairman and Srinivas Akkaraju, MD, PhD as director.

Inventiva filed its 2024 Half-Year Report with the AMF, noting material uncertainty related to its going concern status. The report is available on Inventiva's and AMF's websites. Inventiva focuses on developing oral therapies for MASH/NASH and other unmet medical needs, with lanifibranor in pivotal Phase III trial for MASH/NASH.

Improved liver health biomarkers and reduced scarring observed in MASH patients in lanifibranor Phase 3 trial, similar to Phase 2b NATIVE trial results. NATiV3 trial, enrolling 837 patients, aims to assess MASH resolution and fibrosis reduction at week 72, with interim data showing improved liver function and reduced fibrosis.

Inventiva reports progress in NATiV3 trial with 85% patient enrollment, consistent baseline characteristics, and positive biomarker evolution. The company anticipates last patient randomization in H1 2025 and topline results in H2 2026. Financial update shows cash and cash equivalents at €10.1 million as of June 30, 2024, with a cash runway extended until mid-October 2024 following a €20.1 million royalty deal. Inventiva is actively seeking additional financing and discussing strategic options.